Ziopharm oncology inc (ZIOP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-117,796

-53,117

-54,323

-165,297

-120,088

-31,781

-57,107

-96,132

-63,778

-32,670

-7,649

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

629

575

369

290

357

-

-

-

-

-

-

Stock-based compensation

7,341

7,534

8,454

8,452

7,997

4,743

3,507

4,880

2,759

3,637

2,181

Non-cash inducement warrant expense

60,751

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

462

738

658

268

188

330

Change in fair value of warrants

-

-

-

-

-

11,723

1,185

6,050

7,583

-8,889

4,461

Common stock issued in exchange for license agreement

-

-

-

-

67,285

-

-

18,694

17,457

-

-

Preferred stock issued in exchange for 2016 ECP amendment

-

-

-

118,936

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

0

158

-1,295

-124

-

-

-

-

-

-

-

Issuance of common stock in a license agreement

-

-

-

87

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-585

-48

0

-

-

Change in operating assets and liabilities:
(Increase) decrease in:
Receivables

1,466

1,845

-2

-425

301

-

87

-21

79

-

-

Prepaid expenses and other current assets

1,729

1,263

-3,992

12,452

10,214

-809

-4,964

5,599

889

70

27

Deposits

-2

-

-

-

-

-

-

43

4

41

-41

Other noncurrent assets

-9,431

-3,942

12,991

-

3

-37

-477

230

407

122

-49

Increase (decrease) in:
Accounts payable

199

-3,709

4,261

-1,852

4

1,582

-1,087

-218

696

-758

-850

Accrued expenses

1,725

-1,145

800

203

1,724

827

-10,159

5,695

8,283

1,277

-1,876

Deferred revenue

-

-146

-6,389

-6,861

-

-

-

-

-

-

-

Contract liabilities

-

-

-

-

53,418

-1,373

-800

-800

4,333

-

-

Deferred rent

0

-125

-139

-380

-189

-213

625

244

109

-24

-32

Lease liabilities

63

-

-

-

-

-

-

-

-

-

-

Other noncurrent liabilities

-

-

-

-

-

-20

20

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

0

-

-

Net cash used in operating activities

-40,854

-49,457

-54,669

-58,325

-10

-36,650

-59,509

-78,832

-38,835

-19,694

-12,294

Cash flows from investing activities:
Purchases of property and equipment

284

459

737

551

412

193

132

1,559

1,156

186

11

Proceeds from sale of property and equipment

-

-

-

-

-

-

1

-

0

-

-

Net cash used in investing activities

-284

-459

-737

-551

-412

-193

-131

-1,559

-1,156

-186

-11

Cash flows from financing activities:
Stockholders' capital contribution

-

-

-

-

-

-

-

-

0

-

-

Proceeds from exercise of stock options

1,219

240

88

714

4,568

1,386

956

30

980

225

73

Issuance of restricted common stock

-

-

2,059

1,500

518

-

-

-

-

-

-

Repurchase of common stock

653

1,622

0

2

34

-

-

546

274

1,668

380

Proceeds from issuance of common stock, net

-

-

47,270

-

94,320

-

53,880

49,170

71,207

32,804

49,793

Proceeds from underwritten financing

-

47,101

-

-

-

-

-

-

-

-

-

Repurchase of restricted common stock

-

-

-

-

-

544

498

-

-

-

-

Issuance of common stock upon exercise of warrants, net

52,499

-

-

-

-

10,600

200

330

12,399

72

279

Issuance of common stock in connection with an at the market offering, net

6,085

-

-

-

-

-

-

-

-

-

-

Cash paid for settlement of related party relationship

-

-5,408

-

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock, net

-

-

-

-

-

-

-

-

0

-

-

Net cash provided by financing activities

59,150

40,311

45,299

-788

98,336

11,442

54,538

48,984

84,312

31,433

49,765

Net increase (decrease) in cash and cash equivalents, and restricted cash

18,012

-9,605

-10,107

-59,664

97,914

-25,401

-5,102

-31,407

44,321

11,553

37,460

Supplementary disclosure of cash flow information:
Bonus paid in common stock

1,000

-

-

-

-

-

-

-

-

-

-

Fixed assets in accrued expenses

358

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

0

0

0

0

0

0

0

0

Cash paid for income taxes

-

-

-

0

0

0

0

0

0

0

0

Supplementary disclosure of noncash investing and financing activities:
Noncash portion of related party relationship settlement

-

212,769

-

-

-

-

-

-

-

-

-

Warrants issued to placement agents and investors

-

-

-

-

-

-

-

-

0

-

27,068

Exercise of equity-classified warrants to common shares

-

-

-

-

-

692

196

-

-

-

-

Exercise of liability-classified warrants to common shares

-

-

-

-

-

54

-

412

303

49

-

Issuance of stock

-

-

-

-

67,285

-

-

-

-

-

-

Series 1 Preferred Stock
Change in fair value of derivative liabilities

1

-

-

-

-

-

-

-

-

-

-

Payment of dividends in preferred stock

-

16,998

18,938

7,123

-

-

-

-

-

-

-

Series 1 preferred stock issued as consideration for a license agreement

-

-

-

119,045

-

-

-

-

-

-

-